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Anabolic biosynthesis requires precursors supplied by the Krebs cycle, which in turn requires anaplerosis to replenish
precursor intermediates. The major anaplerotic sources are pyruvate and glutamine, which require the activity of pyruvate
carboxylase (PC) and glutaminase 1 (GLS1), respectively. Due to their rapid proliferation, cancer cells have increased anabolic
and energy demands; however, different cancer cell types exhibit differential requirements for PC- and GLS-mediated
pathways for anaplerosis and cell proliferation. Here, we infused patients with early-stage non–small-cell lung cancer (NSCLC)
with uniformly 13C-labeled glucose before tissue resection and determined that the cancerous tissues in these patients
had enhanced PC activity. Freshly resected paired lung tissue slices cultured in 13C6-glucose or 13C5,15N2-glutamine tracers
confirmed selective activation of PC over GLS in NSCLC. Compared with noncancerous tissues, PC expression was greatly
enhanced in cancerous tissues, whereas GLS1 expression showed no trend. Moreover, immunohistochemical analysis of
paired lung tissues showed PC overexpression in cancer cells rather than in stromal cells of tumor tissues. PC knockdown
induced multinucleation, decreased cell proliferation and colony formation in human NSCLC cells, and reduced tumor growth
in a mouse xenograft model. Growth inhibition was accompanied by perturbed Krebs cycle activity, inhibition of lipid and
nucleotide biosynthesis, and altered glutathione homeostasis. These findings indicate that PC-mediated anaplerosis in earlystage NSCLC is required for tumor survival and proliferation.

Introduction

Accelerated glycolysis under aerobic conditions (the “Warburg
effect”) has been a hallmark of cancer for many decades (1). It is
now recognized that cancer cells must undergo many other metabolic reprogrammings (2) to meet the increased anabolic and
energetic demands of proliferation (3, 4). It is also becoming clear
that different cancer types may utilize a variety of metabolic adaptations that are context dependent (5–11), commensurate with
the notion that altered metabolism is a hallmark of cancer (12).
Enhanced glucose uptake and aerobic glycolysis generates both
energy (i.e., ATP) and molecular precursors for the biosynthesis
of complex carbohydrates, sugar nucleotides, lipids, proteins, and
nucleic acids (3, 13, 14). However, increased glycolysis alone is
insufficient to meet the total metabolic demands of proliferating
cancer cells. The Krebs cycle is also a source of energy via the oxidation of pyruvate, fatty acids (15), and amino acids such as glutamine (10, 16, 17). Moreover, several Krebs cycle intermediates
are essential for anabolic and glutathione metabolism, including
citrate, oxaloacetate, and α-ketoglutarate (Figure 1A).
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Continued functioning of the Krebs cycle requires the replenishment of intermediates that are diverted for anabolic uses or
glutathione synthesis. This replenishment process, or anaplerosis, is accomplished via 2 major pathways: glutaminolysis (deamidation of glutamine via glutaminase [GLS] plus transamination
of glutamate to α-ketoglutarate) (18, 19) and carboxylation of
pyruvate to oxaloacetate via ATP-dependent pyruvate carboxylase (PC) (EC 6.4.1.1) (refs. 3, 20, 21, and Figure 1A). The relative
importance of these pathways is likely to depend on the nature of
the cancer and its specific metabolic adaptations, including those
to the microenvironment (20, 22).
For example, glutaminolysis was shown to be activated in the
glioma cell line SF188, while PC activity was absent (17), despite
the high PC activity present in normal astrocytes (23, 24). However, SF188 cells use PC to compensate for GLS1 suppression or
glutamine restriction (20), and PC, rather than GLS1, was shown
to be the major anaplerotic input to the Krebs cycle in primary
glioma xenografts in mice (22). It is also unclear as to the relative
importance of PC and GLS1 in other cancer cell types or, most
relevantly, in human tumor tissues in situ. Our preliminary evidence from 5 non–small-cell lung cancer (NSCLC) patients indicated that PC expression and activity are upregulated in cancerous
(CA) compared with paired noncancerous (NC) lung tissues (21),
although it was unclear whether PC activation applies to a larger
NSCLC cohort or whether PC expression was associated with the
cancer and/or stromal cells. Nor has the relationship between PC
activation and glutaminase status been explored in human patient
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studies. Moreover, the role of PC in cell survival and proliferation
and whether glutaminolysis can compensate for this role under PC
suppression in lung cancer cells is unknown.
Here, we have greatly extended our previous findings (21) in a
larger cohort (n = 86) by assessing glutaminase 1 (GLS1) status and
analyzing in detail the biochemical and phenotypic consequences
of PC suppression in NSCLC. We found PC activity and protein
expression levels to be, on average, respectively, 100% and 5- to
10-fold higher in cancerous (CA) lung tissues than in paired NC
lung tissues resected from NSCLC patients, whereas GLS1 expression showed no significant trend. We have also applied stable
isotope–resolved metabolomic (SIRM) analysis to paired freshly
resected CA and NC lung tissue slices in culture (analogous to the
Warburg slices; ref. 25) using either [U-13C] glucose or [U-13C,15N]
glutamine as tracers. This novel method provided information
about tumor metabolic pathways and dynamics without the complication of whole-body metabolism in vivo. We used immunohistochemical analysis to verify the specific localization of PC in
cancer cells within the tumor tissue. We further determined the
functional role of PC in NSCLC cell lines using shRNA, which
showed that attenuation of PC activity inhibited cell proliferation,
colony formation, and tumor growth in mouse xenografts, while
compromising the cells’ ability to quench oxygen radicals. These
phenotypic effects can be linked to several important metabolic
outcomes of PC suppression in the lung adenocarcinoma A549
cell line cultured in vitro and in vivo, including reduced lipid and
nucleotide biosynthesis and altered glutathione homeostasis.

Results

PC expression and activity, but not glutaminase expression, are significantly enhanced in early stages of malignant NSCLC tumors. PC
protein expression was significantly higher in primary NSCLC
tumors than in paired adjacent NC lung tissues (n = 86, P < 0.0001,
Wilcoxon test) (Figure 1, B and C). The median PC expression was
7-fold higher in the tumor, and the most probable (modal) overexpression in the tumor was approximately 3-fold higher (see Supplemental Table 1; supplemental material available online with this
article; doi:10.1172/JCI72873DS1). We found that PC expression
was also higher in the tumor tissue compared with that detected
in the NC tissue in 82 of 86 patients. In contrast, GLS1 expression
was not significantly different between the tumor and NC tissues
(P = 0.213, Wilcoxon test) (Figure 1C and Supplemental Table 1).
To estimate in vivo PC activity, the production of 13C3-Asp from
13
C6-glucose (Figure 1A) infused into NSCLC patients was determined by gas chromatography–mass spectrometry (GC-MS). A
bolus injection of 10 g 13C6-glucose in 50 ml saline led to an average of 44% 13C enrichment in the plasma glucose immediately
after infusion (Supplemental Table 2). Because the labeled glucose
was absorbed by various tissues over the approximately 2.5 hours
between infusion and tumor resection, plasma glucose enrichment
dropped to 17% (Supplemental Table 2). The labeled glucose in both
CA and NC lung tissues was metabolized to labeled lactate, but this
occurred to a much greater extent in the CA tissues (Supplemental
Figure 1A), which indicates accelerated glycolysis in these tissues.
The enrichment of 13C3-Asp (a PC marker, Figure 1A) was on
average 117% higher (n = 34, P < 0.005) in NSCLC tumors than
in NC lung tissue (Figure 1D). 13C3-Asp can also be produced after
2

the second turn of the Krebs cycle via 13C4-citrate, which is the
condensation product of 13C2-acetyl CoA and 13C2-oxaloacetate
(OAA). Since the 13C enrichment of the 13C4-citrate precursor was
lower than that of the 13C3-Asp product (Supplemental Figure 1,
B and C, and Figure 1D), it argues against a significant contribution of this route to 13C3-Asp enrichment. We also measured
PC activity by the fractional 13C enrichment of other markers,
13
C3-citrate, 13C5-citrate, and 13C3-malate, which were, respectively, 27%, 88%, and 113% higher in CA lung tissues than in NC
lung tissues (Figure 1D). We also observed that 13C3-citrate was
5- to 6-fold higher in fractional enrichment than was 13C5-citrate
for both CA and NC lungs. This could be attributed to the expectedly low 13C enrichment in pyruvate and thus acetyl CoA due
to a large dilution of the 13C-glucose tracer in the human body,
leading to a lower probability of condensation of 13C3-OAA with
13
C2-acetyl CoA than with unlabeled acetyl CoA to produce less
13
C5-citrate than 13C3-citrate. Moreover, the fractional enhancement of 13C3-citrate in CA over NC lungs was less than that of
13
C5-citrate (Figure 1D). This could be a result of increased flux
through the pyruvate dehydrogenase–initiated (PDH-initiated)
Krebs cycle reactions in CA lung compared with that in NC lung,
as evidenced by the elevated fraction of 13C2 isotopologs of Krebs
cycle metabolites in CA versus NC lung (Supplemental Figure
1B). This could in turn lead to a relatively higher enrichment of
13
C2-acetyl CoA and thus its product (13C5-citrate) of condensation with 13C3-OAA in CA lung compared with that in NC lung.
Altogether, the significant increase in the fractional enrichment
of these PC markers reflects increased PC activity (which we
refer to herein) in the cancer tissue.
In addition to enhanced production of labeled PC markers, we
observed a higher percentage of enrichment in the 13C2-isotopologs
of Krebs cycle metabolites (citrate+2, glutamate+2, succinate+2,
fumarate+2, malate+2, and aspartate+2 in Supplemental Figure
1B) in NSCLC tumors than in NC lung tissue, which is indicative of
enhanced glucose oxidation in the Krebs cycle via PDH.
Fresh tissue (Warburg) slices confirm enhanced PC and Krebs cycle
activity in NSCLC. To further assess PC activity relative to GLS1
activity in human lung tissues, thin (<1 mm thick) slices of paired
CA and NC lung tissues freshly resected from 13 human NSCLC
patients were cultured in 13C6-glucose or 13C5,15N2-glutamine for 24
hours. These tissues maintain biochemical activity and histological integrity for at least 24 hours under culture conditions (Figure
2A, Supplemental Figure 2, A and B, and ref. 26). When the tissues
were incubated with 13C6-glucose, CA slices showed a significantly
greater percentage of enrichment in glycolytic 13C3-lactate (3 in
Figure 2B) than did the NC slices, indicative of the Warburg effect.
In addition, the CA tissues had significantly higher fractions of
13
C4-, 13C5-, and 13C6-citrate (4, 5, and 6 of citrate, respectively, in
Figure 2B) than did the NC tissues. These isotopologs require the
combined action of PDH, PC, and multiple turns of the Krebs cycle
(Figure 2C). Consistent with the labeled citrate data, the increase in
the percentage of enrichment of 13C3-, 13C4-, and 13C5-glutamate (3,
4, and 5 of glutamate, respectively, in Figure 2B) in the CA tissues
indicates enhanced Krebs cycle and PC activity.
When tissue slices were incubated with 13C5,15N2-glutamine,
13
C5,15N1-glutamate (6 of glutamate in Supplemental Figure 2C)
was produced in both CA and NC tissues, indicating active gluta-
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Figure 1. PC is activated in human NSCLC tumors.
(A) PC and GLS1 catalyze the major anaplerotic
inputs (blue) into the Krebs cycle to support the
anabolic demand for biosynthesis (green). Also
shown is the fate of 13C from 13C6-glucose through
glycolysis and into the Krebs cycle via PC (red).
(B) Representative Western blots of PC and GLS1
protein expression levels in human NC lung (N)
and NSCLC (C) tissues. (C) Pairwise PC and GLS1
expression (n = 86) was normalized to α-tubulin
and plotted as the log10 ratio of CA/NC tissues. For
PC, nearly all log ratios were positive (82 of 86),
with a clustering in the 0.5–1 range (i.e., typically
3- to 10-fold higher expression in the tumor tissue; Wilcoxon test, P < 0.0001). In contrast, GLS1
expression was nearly evenly distributed between
positive and negative log10 ratios and showed no
statistically significant difference between the
CA and NC tissues (Wilcoxon test, P = 0.213). Horizontal bar represents the median. (D) In vivo PC
activity was enhanced in CA tissue compared with
that in paired NC lung tissues (n = 34) resected
from the same human patients given 13C6-glucose
2.5–3 hours before tumor resection. PC activity
was inferred from the enrichment of 13C3-citrate
(Cit+3), 13C5-Cit (Cit+5), 13C3-malate (Mal+3), and
13
C3-aspartate (Asp+3) as determined by GC-MS.
*P < 0.05 and **P < 0.01 by paired Student t test.
Error bars represent the SEM.

minase (see below). In addition, the 13C4-isotopologs of succinate,
fumarate, malate (data not shown), and citrate (Supplemental
Figure 2C) were detected, which confirms glutaminase action.
However, the enrichment patterns of all but 1 isotopolog of the
Krebs cycle intermediates derived from 13C5,15N2-glutamine were
comparable between CA and NC tissues (Supplemental Figure
2C). These data, along with the GLS1 expression data (Figure 1C),
indicate that GLS1 is active and likely a significant player in the
anaplerosis of the Krebs cycle in both types of tissues. But unlike
PC, GLS1 was not significantly activated in NSCLC tumors relative to that seen in NC lung tissues.
PC is localized in the cancer cells within NSCLC tumors.
NSCLC tumors are very heterogeneous and comprise various
cell types including cancerous epithelial cells, pneumocytes,
fibroblasts, endothelial cells, and immune cells such as macrophages. To determine whether PC is expressed specifically in
cancer cells, we performed immunohistochemical analysis of
paired CA and NC tissues from 9 patient samples. Figure 3 and
Supplemental Figure 3 illustrate elevated PC levels in 4 NSCLC

tumors compared with levels in the paired
NC lung tissue, which was also evident in
5 other pairs of samples (data not shown)
and is consistent with the Western blot data
(Figure 1C). Moreover, PC was localized
in the perinuclear region of the cancerous epithelial cells but not in stromal cells
in the tumor tissue (Figure 3, bottom left
panel, and Supplemental Figure 3D). Such
a perinuclear staining pattern is consistent
with the localization of PC in the mitochondria, which is supported by the perinuclear
costaining of PC and the mitochondrial marker in NSCLC A549
cells (Supplemental Figure 3, C and D).
In contrast, in the NC lung tissue, only macrophages were
enriched in PC, while PC in other cell types stained weakly or
was absent (Figure 3 and Supplemental Figure 3). Thus, PC is
preferentially localized in the cancer cells of heterogeneous
lung tumor tissues.
PC suppression by shRNA in lung cancer cells leads to growth arrest
and decreased tumor burden in vivo. In order to assess the role of PC
in the survival and growth of lung cancer cells, we used PC-specific
shRNA to suppress PC mRNA expression in human A549 adenocarcinoma cells. As shown in Supplemental Figure 4A, vector shPC54
reduced PC protein levels to 20% of the control levels, whereas PC
expression was barely detected in cells transduced with shPC55.
To verify the inhibition of PC activity in cells, we incubated empty
vector– (shEV), shPC54-, and shPC55-transduced A549 cells in
13
C6-glucose for 24 hours and measured the markers for PC activity
by GC-MS (Figure 1A). The levels of 13C3-citrate, 13C3-aspartate, and
13
C3-malate were reduced by both constructs; however, shPC55 was
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the net growth of all cell lines tested
(Figure 4A). HCC827 and PC9 cells
were more sensitive to PC knockdown than were A549, H2030, or
H1299 cells. HCC827 and PC9 cells
also expressed more PC than did
A549 and H1299 (Supplemental
Figure 5A). The colony-formation
assay revealed that PC knockdown
significantly inhibited the ability of
A549 and PC9 cells to form colonies
in soft agar (Figure 4B). Although
PC suppression did not reduce the
total number of colonies produced
by H1299 cells (Figure 4B), it dramatically affected the size of each
colony (Supplemental Figure 5B),
which is consistent with slower cell
growth (Figure 4A). Moreover, PCsuppressed cells became large and
multinucleated, and the degree of
multinucleation increased over time
(Supplemental Figure 6, A–C).
We then determined whether
PC-suppressed A549 cells are
compromised in tumor growth in
immune-deficient mice. We followed the rate of tumor growth after
injecting NSG mice with A549 cells
transduced with an empty vector
(shEV) or shPC55 (shPC). PC knockFigure 2. Ex vivo CA lung tissue slices have enhanced oxidation of glucose through glycolysis and the
down resulted in a 2-fold slower
Krebs cycle with and without PC input compared with that of paired NC lung slices. Thin slices of CA
13
rate
of tumor growth (P = 0.001), as
and NC lung tissues freshly resected from 13 human NSCLC patients were incubated with C6-glucose
assessed by quadratic curve fitting
for 24 hours as described in the Methods. The percentage of enrichment of lactate, citrate, glutamate,
and aspartate was determined by GC-MS. (A) 1H{13C} HSQC NMR showed an increase in labeled lactate,
of the tumor growth kinetics (Figure
glutamate, and aspartate. In addition, CA tissues had elevated 13C abundance in the ribose moiety of the
4C and Supplemental Table 3). We
adenine-containing nucleotides (1′-AXP), indicating that the tissues were viable and had enhanced capacfound that decreased tumor growth
ity for nucleotide synthesis. (B) CA tissue slices (n = 13) showed increased glucose metabolism through gly13
was clear by day 14 (P = 0.009). In
colysis based on the increased percentage of enrichment of C3-lactate (“3”), and through the Krebs cycle
addition, endpoint analysis of tumor
based on the increased percentage of enrichment of 13C4–6-citrate (“4–6”) and 13C3–5-glutamate (“3–5”) (see
13
C fate tracing in C). *P < 0.05 and **P < 0.01 by paired Student’s t test. Error bars represent the SEM. (C)
weights showed a 30% smaller
An atom-resolved map illustrates how PC, PDH, and 2 turns of the Krebs cycle activity produced the 13C iso- tumor in the shPC55 xenografts comtopologs of citrate and glutamate in B, whose enrichment were significantly enhanced in CA tissue slices.
pared with that observed in the shEV
xenografts (P = 0.0073). However,
the knockdown did not remain as
effective in vivo as in cell culture. We found that PC expression in
more effective than shPC54 (Supplemental Figure 4B). It is interestthe knockdown tumors after 36 days had increased to 30% to 60%
ing to note that increased PC activity may occur in other unrelated
of that in tumors with control empty vector (Supplemental Figure
transformed cell lines (3, 27). PC knockdown slowed cell growth,
7A). Interestingly, the growth rate of individual tumors correlated
again with shPC55 being more effective than shPC54 (Supplemental
significantly (P = 0.006) with their level of PC expression (Figure
Figure 4C). This corroborates the greater extent of PC knockdown
4D). Therefore, residual PC expression is likely to account for the
by shPC55 (Supplemental Figure 4A). Furthermore, PC knockdown
limited ability of the shPC55 tumors to grow. Altogether, these data
greatly decreased the number of colonies formed in soft agar (Supindicate that PC expression is important for in vivo tumor growth.
plemental Figure 4D), reduced cell viability (Supplemental Figure
PC knockdown perturbs Krebs cycle activity, the anabolic capacity
4E), and altered morphology (Supplemental Figure 4F).
of the cell, and glutathione homeostasis. To investigate the metabolic
Since shPC55 was the more effective construct in suppressing
consequences of PC knockdown, A549 cells were transduced with
both PC expression and activity, we used it to probe the effects of
shPC55, grown in 13C6-glucose or 13C5,15N2-glutamine, and incorpoPC suppression on the additional NSCLC adenocarcinoma cell
lines H1299, H2030, HCC827, and PC9. PC knockdown inhibited
ration of the label was analyzed by NMR and MS. In addition, the
4

jci.org

Downloaded from http://www.jci.org on January 22, 2015. http://dx.doi.org/10.1172/JCI72873

Research article

The Journal of Clinical Investigation  

ciency in NSCLC cells. shPC55- or shEV-transduced A549
cells were incubated with 13C5,15N2-glutamine to track glutaminolysis. As shown in Figure 5B, GLS1 activity can produce
13
C5,15N1-glutamate (6) from 13C5,15N2-glutamine (7), which
subsequently enters the Krebs cycle to generate 13C4-succinate
(4), 13C4- (4) or 13C4,15N1-aspartate (5), and 13C4-citrate (4). A549
cells readily took up and metabolized 13C5,15N2-glutamine
into these labeled metabolites. However, the levels of all
these labeled isotopologs were significantly reduced in the
PC-knockdown cells (highlighted by red circles in Figure 5B),
which is consistent with reduced GLS activity. Decreased
GLS activity was also evident in the 1H-{13C} HSQC spectra, which showed that PC-suppressed cells incorporated
less glutamine carbon into glutamate, aspartate, and citrate
(Supplemental Figure 9B). It should be noted that amidotransferase activity can also contribute to the production of
the labeled products shown in Figure 5B and Supplemental
Figure 9B. However, changes in amidotransferase activity
Figure 3. Immunohistochemical localization of PC in lung tissues. Pairs of
are unlikely to account for the observed blockage of Gln
CA and NC tissues obtained from NSCLC patients were stained with anti-PC
metabolism induced by PC knockdown. This is because
antibody. Shown are representative pairs of micrographs from 1 patient. Original
PC knockdown in A549 cells or in mouse xenografts led to
magnification, ×400 (top panels) and ×600 (bottom panels). Additional patient
data are provided in Supplemental Figure 3. In CA tissues, viable cancer cells
suppressed GLS1 expression (Supplemental Figure 10A).
stained intensely for PC, while macrophages stained weakly, and other stromal
In addition, A549 cells exhibited high GLS1 expression and
cells showed no staining for PC. In adjacent NC tissues, macrophages stained
GLS activity in cell lysates, suggesting that GLS1 expression
strongly for PC, while pneumocytes stained very weakly for the protein.
is important for A549 cell growth (see below).
To further probe the importance of glutamine utilization in PC-suppressed cells, A549 cells were incubated with
either 2 or 0.2 mM glutamine. We found that glutamine restriction
mice engrafted with shPC55- or shEV-transduced A549 cells were
significantly reduced the growth rate of control cells by approxiinjected with 13C6-glucose. With the glucose tracer, we found no evimately 30%, but had no influence on PC-knockdown cells (Supdence that PC affects aerobic glycolysis, as PC-knockdown cells had
plemental Figure 10, B and C). Thus, glutaminolysis does not comsimilar glucose consumption and production of total and labeled
pensate for the loss of PC as an anaplerotic supplier of precursors
lactate in the media (Supplemental Figure 7B). In addition, the lacto the Krebs cycle intermediates in NSCLC cells.
tate released into the media had the same percentage of enrichment
Beyond supplying reducing equivalents and energy (ATP
pattern in PC-knockdown and control cells (Supplemental Figure
and GTP), the Krebs cycle also supplies various precursors for
7C). Likewise, mouse tumors bearing shEV or shPC55 had compaanabolism. For instance, citrate is exported from the mitochonrable concentrations of total lactate, labeled lactate derived from
13
dria to supply acetyl CoA for fatty acid synthesis; OAA is transamC6-glucose (Supplemental Figure 7D), and percentage of lactate
inated to aspartate for pyrimidine biosynthesis; α-ketoglutarate
enrichment patterns (Supplemental Figure 7E).
is aminated to glutamate for de novo glutathione synthesis; and
In contrast, PC knockdown reduced the oxidation of
13
malate is decarboxylated to pyruvate, providing NADPH for lipid
C6-glucose through the Krebs cycle. As expected, entry of glybiosynthesis and glutathione reduction (Figure 1A). To determine
colytic 13C3-pyruvate into the Krebs cycle via PC was inhibited, as
how perturbation of the Krebs cycle by PC suppression affects
indicated by the reduced production of various 13C3 isotopologs and
13
these anabolic pathways, we used SIRM to follow the biosyntheC5-citrate (highlighted by blue circles in Figure 5A). Interestingly,
sis of nucleotides, lipids, and glutathione in A549 cells grown in
pyruvate entry via PDH was also hindered by PC knockdown (high13
lighted by red circles in Figure 5A). We observed the same trend in
C6-glucose or 13C5-glutamine tracers.
mouse tumors initiated by PC-knockdown cells (Supplemental FigPC knockdown reduced the levels of uracil and adenine
ure 8), although the effects were less severe than those seen in cell
nucleotides both in cell culture and in vivo (Supplemental Figcultures. This is again consistent with the finding that A549 cells
ure 11, A and B). These changes were at least in part attributed to
with PC knockdown were able to recover PC expression to some
attenuated biosynthesis of these nucleotides by PC knockdown,
extent in vivo (Supplemental Figure 7A). Reduced glucose oxidaas evidenced by the reduced incorporation of labeled glucose
tion through the Krebs cycle in cells and tumors was also observed
into the C1′ ribose carbon observed in HSQC NMR analysis of
1
by 1H-{13C} heteronuclear single-quantum coherence (HSQC)
H{13C} (Supplemental Figure 9A and Supplemental Figure 11A).
NMR (Supplemental Figure 9, A and C), which showed reduced
This can be accounted for by the reduced production of the uraincorporation of 13C from the glucose tracer into citrate, aspartate,
cil and cytosine ring via decreased synthesis of their precursor
aspartate from glucose and glutamine both in cells (Figure 5) and
glutamate, and the glutamate residue of glutathione.
in vivo (Supplemental Figure 8). Consistently, we observed less
Since glutaminolysis is another major anaplerotic pathway,
incorporation of the glucose and glutamine carbon into the ring
we asked whether this pathway could compensate for PC defijci.org
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accumulated in the PC-knockdown cells (Figure
6B). Likewise, fatty acyl synthesis from 13C5-glutamine (“Even” in Figure 6B) via glutaminolysis and the Krebs cycle was greatly attenuated
in PC-suppressed cells. Taken together, these
results suggest that PC knockdown severely
inhibits lipid production by blocking the biosynthesis of fatty acyl components but not the glucose-derived glycerol backbone. This is consistent with decreased Krebs cycle activity (Figure
5), which in turn curtails citrate export from the
mitochondria to supply the fatty acid precursor
acetyl CoA in the cytoplasm.
Finally, de novo glutathione synthesis was
analyzed by 1H{13C} HSQC NMR. Glutathione
synthesis from both glucose and glutamine
was suppressed by PC knockdown (Supplemental Figure 9, A and B). Reduced de novo
synthesis led to a large decrease in the total
level of reduced glutathione (GSH; Supplemental Figure 12, A and B). At the same time,
PC-knockdown cells accumulated slightly
more oxidized GSH (GSSG; Supplemental
Figure 12, A and B), leading to a significantly
Figure 4. PC suppression via shRNA inhibits proliferation and tumorigenicity of human
reduced
GSH/GSSG ratio both in cell culture
NSCLC cell lines in vitro and in vivo. Proliferation and colony-formation assays were initiated
and
in
vivo
(Supplemental Figure 12C). To
1 week after transduction and selection with puromycin. A549 xenograft in NSG mice was perdetermine whether this perturbation of glutaformed 8 days after transduction. *P < 0.01, **P < 0.001, ***P < 0.0001, and ****P < 0.00001
by Student t test, assuming unequal variances. Error bars represent the SEM. (A) NSCLC cells
thione homeostasis compromises the ability of
lines were transduced with shPC55 or shEV. Proliferation assays (n = 6) revealed substantial
PC-suppressed cells to handle oxidative stress,
growth inhibition induced by PC knockdown in all 5 cell lines after a relatively long latency
we measured ROS production by DCFDA fluoperiod. (B) Colony-formation assays indicated that PC knockdown reduced the capacity of A549
and PC9 cells to form colonies in soft agar (n = 3). (C) Tumor xenografts from shPC55-transduced rescence. PC-knockdown cells had over 70%
more basal ROS than did control cells (0 mM
A549 cells showed a 2-fold slower growth rate than did control shEV tumors (P < 0.001 by the
unpaired Welch version of the t test). Tumor size was calculated as πab/4, where a and b are
H2O2; Supplemental Figure 12D). When cells
the x,y diameters. Each point represents an average of 6 mice. The solid lines are the nonlinear
were exposed to increasing concentrations of
regression fits to the equation: size = a + bt2, as described in the Methods. (D) The extent of
H2O2, the knockdown cells were less able to
PC knockdown in the mouse xenografts (n = 6) was lesser than that in cell cultures, leading to
quench
ROS, as they produced up to 300%
less attenuation of PC expression (30%–60% of control) and growth inhibition. In addition, PC
more ROS than did control cells (Supplemenexpression in the excised tumors correlated with the individual growth rates, as determined by
Pearson’s correlation coefficient.
tal Figure 12D). However, N-acetylcysteine
(NAC) at 10 mM did not rescue the growth of
PC-knockdown cells, suggesting that such a
growth effect is not simply related to an inability to regenerate
of UTP and CTP by Fourier transform ion cyclotron resonance
GSH from GSSG. Altogether, these results show that PC suppres(FT-ICR-MS) analysis (Figure 6A).
sion compromises anaplerotic input into the Krebs cycle, which
Lipid biosynthesis was assessed in the nonpolar fractions of the
in turn reduces the activity of the Krebs cycle, while limiting the
same cell extracts by FT-ICR-MS, which can resolve a large number
ability of A549 cells to synthesize nucleotides, lipids, and glutaof intact lipids and determine their 13C enrichments in the glycerol
thione. These downstream effects of PC knockdown were also
and fatty acyl components (28). PC knockdown greatly inhibited
evident when comparing the metabolism of shPC55-transduced
synthesis of the major cell membrane components phosphatidA549 cells against that of A549 cells transduced with a scramylcholines from both glucose and glutamine tracers (Figure 6B).
bled vector (shScr) (Supplemental Figure 13), which suggests
Using 13C6-glucose as a tracer, 13C was incorporated extensively into
that they are on-target effects of PC knockdown.
the glycerol backbone (3 13C atoms), fatty acyl chains (even 13C), and
Glutaminolysis is also a functionally significant source of anapleglycerol plus fatty acyl residues (odd >3 13C) in shEV control cells
rosis in NSCLC. To determine whether GLS1 is functionally impor(28). With PC suppression, almost all phosphatidylcholine species
tant for NSCLC cells, we suppressed GLS1 expression by shRNA
were either unlabeled (as 0) or labeled at the glycerol backbone
in both A549 and H1299, which resulted in reduced growth rates
only (as 3), while the 13C isotopologs reflecting fatty acyl synthesis
in both cells (Supplemental Figure 14, A and B). The growth of
from glucose (even and odd >3) were greatly diminished in A549
A549, H1299, and PC9 cells also decreased in response to BPTES
cells. In addition, the glycerol backbone precursor α-glycerol-3(a known GLS inhibitor) treatment (Supplemental Figure 14C).
phosphate (αG3P) (such as 13C3-αG3P derived from 13C6-glucose)
6
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Figure 5. PC knockdown perturbs glucose and glutamine flux through the Krebs cycle. 13C Isotopolog concentrations were determined by GC-MS (n = 3).
Values represent the averages of triplicates, with standard errors. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001 by Student’s t test, assuming
unequal variances. The experiments were repeated 3 times. (A) A549 cells were transduced with shPC55 for 10 days before incubation with 13C6-glucose
for 24 hours. As expected, the 13C isotopologs of Krebs cycle metabolites produced via PC and Krebs cycle activity were depleted in PC-deficient cells
(tracked by blue dots in the atom-resolved map and blue circles in the bar graphs; see also Figure 2C). In addition, 13C6-glucose metabolism via PDH was
also perturbed (indicated by red dots and circles). (B) Treatment of PC-knockdown cells with 13C5,15N2-glutamine revealed that anaplerotic input via GLS
did not compensate for the loss of PC activity, since GLS activity was attenuated, as inferred from the activity markers (indicated by red dots and circles).
Decarboxylation of glutamine-derived malate by malic enzyme (ME) and reentry of glutamine-derived pyruvate into the Krebs cycle via PC or PDH (shown
in blue and green, respectively) were also attenuated. Purple diamonds denote 15N; black diamonds denote 14N.

Further, 13C isotopolog analysis of these 3 cell lines after incubation with 13C5,15N2-Gln showed that they used glutamine as a significant source of carbon for the Krebs cycle (Supplemental Figure
14D). Therefore, it appears that both GLS1 and PC are important
for supporting proliferation and Krebs cycle activity in NSCLC
cells. 13C5,15N2-Gln as a substantial carbon source for the Krebs

cycle was also recapitulated in the human tissue slice data (Supplemental Figure 2C). However, unlike PC-based anaplerosis (Figure
2B), GLS-fueled anaplerotic activity was comparable between CA
and NC tissue slices (Supplemental Figure 2C), which is consistent
with the lack of discernible distinction in GLS1 protein expression
between bulk CA and NC tissues (Figure 1C).
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Figure 6. PC suppression hinders Krebs cycle–fueled biosynthesis. (A) 13C atom–resolved pyrimidine biosynthesis from 13C6-glucose and 13C5-glutamine
is depicted with a 13C5-ribose moiety (red dots) produced via the pentose phosphate pathway (PPP) and 13C1-3 uracil ring (blue dots) derived from
13
C2-4-aspartate produced via the Krebs cycle or the combined action of ME and PC (blue dots). A549 cells transduced with shPC55 or shEV were incubated with 13C6-glucose or 13C5-glutamine for 24 hours. Fractional enrichment of UTP and CTP isotopologs from FT-ICR-MS analysis of polar cell extracts
showed reduced enrichment of 13C6-glucose–derived 13C5-ribose (the “5” isotopolog) and 13C6-glucose– or 13C5-glutamine–derived 13C1-3-pyrimidine rings
(the “6–8” or “1–3” isotopologs, highlighted by dashed green rectangles; for the “6–8” isotopologs, 5 13Cs arose from ribose and 1–3 13Cs from the ring)
(10, 45). These data suggest that PC knockdown inhibits de novo pyrimidine biosynthesis from both glucose and glutamine. (B) Glucose and glutamine
carbons enter fatty acids via citrate. FT-ICR-MS analysis of labeled lipids from the nonpolar cell extracts showed that PC knockdown severely inhibited
the incorporation of glucose and glutamine carbons into the fatty acyl chains (even) and fatty acyl chains plus glycerol backbone (odd >3) of phosphatidylcholine lipids. However, synthesis of the 13C3-glycerol backbone (the “3” isotopolog) or its precursor 13C3-α-glycerol-3-phosphate (αG3P, m+3) from
13
C6-glucose was enhanced rather than inhibited by PC knockdown. These data suggest that PC suppression specifically hinders fatty acid synthesis
in A549 cells. Values represent the averages of triplicates (n = 3), with standard errors. *P < 0.05, **P < 0.01, and ***P < 0.001 by Student’s t test,
assuming unequal variances.
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Discussion

Prior to our earlier report (21), the upregulation of PC in NSCLC
was an undocumented phenomenon. Most research on anaplerosis
in cancer cells has focused on the upregulation of glutamine metabolism via GLS1 in established cell lines, which cannot recapitulate
the influence of the tumor microenvironment (17, 29–32). To gain
insights into metabolic reprogramming in human cancer, it is imperative to study human tumors in situ and to compare paired CA and
surrounding NC tissues from the same patient to circumvent cell
culture artifacts, while eliminating confounding intrinsic genetic
and physiological variables. It is also important to implement a fast
and consistent liquid N2–quenching protocol to minimize metabolic
artifacts during tissue sampling after surgical resection.
By addressing the two aspects of our study, we found that
although PC expression and activity in lung tissues varied substantially from patient to patient, 94% of the NSCLC tumors (82
of 86) overexpressed PC, and 73% (25 of 34) showed elevated PC
activity in vivo relative to that in their paired NC lung tissues. This
contrasts with the insignificant difference observed in the expression of GLS1 between CA and NC tissues (Figure 1C). PC was
highly expressed exclusively in cancer cells of early-stage NSCLC
tumor tissues. In contrast, PC was not expressed in the pneumocytes, but its expression was evident in macrophages of paired NC
tissue (Figure 3 and Supplemental Figure 3). We surmise that the
latter may be related to inflammation, which is common in the
lungs of NSCLC patients.
The requirement of PC for NSCLC proliferation and tumorigenesis was demonstrated by PC suppression in several lung
cancer cell lines (Figure 4, A and B) and in vivo for A549 cells (Figure 4, C and D) using specific shRNAs. The long latency period
between mRNA knockdown and phenotypic effects (Figure 4A)
may be related to the long half-life of PC (1–2 d, ref. 33). The intracellular level of PC may need several cell divisions to be attenuated
sufficiently to compromise anaplerosis, leading to reduced cell proliferation. We have verified that inhibition of cell proliferation by
PC suppression is accompanied by a decrease in anaplerotic input
into the Krebs cycle (Figure 5) and the consequent reduction of
nucleotide (Figure 6A, Supplemental Figure 11A, and Supplemental Figure 13C) and lipid biosynthesis (Figure 6B and Supplemental Figure 13D). The correlation of the severity of these metabolic
effects with the efficiency of the knockdown and the inhibition of
cell proliferation both in vitro and in vivo (Figure 4 and Supplemental Figure 4) is consistent with PC knockdown being a significant
contributor to the reduced proliferation. Although we have clearly
demonstrated the importance of PC for cancer cell proliferation
and that enzymic activity is an important aspect of the role of PC,
we cannot rule out the possibility that the protein has alternative
nonenzymic functions in the cells, as has been observed for several
other metabolic enzymes (34).
In addition, PC knockdown in A549 cells greatly depletes the
GSH pool and perturbs glutathione homeostasis (Supplemental Figure 12C) by blocking de novo glutathione synthesis (Supplemental
Figure 12B and Supplemental Figure 13B), which presumably leads
to greater ROS production (Supplemental Figure 12D) and a compromised ability to survive oxidative stress. Exogenous reductants such
as NAC in some circumstances can reduce cellular GSSG to GSH,
but NAC cannot overcome the depleted GSH pool in PC-suppressed

cells, thus accounting for the failure of NAC to rescue PC-suppressed
cells from growth inhibition (Supplemental Figure 12E).
Although active, anaplerotic glutaminolysis could not compensate for lost PC-based anaplerosis in A549 cells (Figure 5B and
Supplemental Figure 10), despite the abundant supply of glutamine.
This is presumably due to the reduced expression of GLS1 in PCknockdown cells or in xenograft tumors (Supplemental Figure 10A).
Moreover, we noted that in the human NSCLC tumors, in which PC
was underexpressed, GLS1 was also underexpressed. These results
suggest that PC and GLS1 are not compensatory in their functions in
human NSCLC, in contrast to some glioma cells (20).
Finally, the improved variant of Warburg’s tissue slices (25)
that we have introduced enables detailed ex vivo analysis of
patient-specific tumor metabolism (Figure 2 and Supplemental
Figure 2), while maintaining most of the tissue microenvironment and cellular heterogeneity without systemic complications
from the blood supply. This ex vivo system also affords versatility of experimental manipulations (e.g., tracer choices or drug
treatments) similar to that of the pure cell culture system. In our
case, enhanced in vivo PC activity (Figure 1D) in human NSCLC
tumor tissues was confirmed by the corresponding ex vivo tracer
studies (Figure 2B). Equally important is that the ex vivo system
enables unequivocal determination of anaplerotic glutaminolysis using the labeled glutamine tracer (Supplemental Figure 2C),
thereby corroborating the lack of in vivo upregulation of GLS1 in
human tumor tissues (Figure 1C). This would have been difficult to
demonstrate in vivo in human patients due to cost considerations.
Thus, the ex vivo tissue culture system can complement existing
model systems for translating bench-to-bedside understanding,
particularly in an individualized manner (26).
In conclusion, our results in primary human lung tumors and ex
vivo tissue slices show that PC protein expression and activity are
enhanced in early stages of human NSCLC tumor tissues compared
with that seen in NC tissues from the same patient and that the PC
protein is localized in the cancer cells within the tumor tissue. Silencing PC expression and activity compromises NSCLC cell growth,
tumorigenicity, and antioxidation capacity. These phenotypic effects
of PC suppression were related to the vital metabolic functions of PC
in NSCLC, including sustaining mitochondrial Krebs cycle activity,
nucleotide and lipid biosynthesis, and redox homeostasis.

Methods

Patient accrual. Eighty-six patients with suspected primary lung cancer but without diagnosed diabetes were recruited on the basis of
their surgical eligibility. The patients were then randomly grouped
into 2 arms. In the first arm, the patients were overnight fasted
(>8 hours) before 10 grams of uniformly labeled 13C glucose was
administered i.v. and again 2.8 ± 0.5 hours prior to video-assisted
thorascopic surgical (VATS) wedge resection, as previously described
in detail (35), to enable tracking of metabolic pathways (21, 36–38).
Patients in the second arm did not receive a glucose injection. We
and others have previously discussed the relative advantages of bolus
injections versus slow-infusion protocols (21, 36–41). The bolus injection leads to an initially high blood glucose concentration, which then
decays to the baseline level, thus limiting the length of time that effective labeling can be achieved but more closely approximating an initial rate condition. In comparison, a prolonged slow infusion can lead
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to a higher degree of isotopic labeling and approach isotopic steadystate conditions, but is a much more involved process, and a true isotopic steady state may be difficult and cost prohibitive to achieve.
The extent of resection was determined by the surgeon according to clinical criteria. The majority of the specimens were obtained
from wedge resections to minimize surgical times, while the remainder were acquired in less than 5 minutes after the pulmonary vein
was clamped; both practices helped avoid development of significant
ischemia in resected tissues. Immediately after resection, the tumor
was transected, and sections of CA tissue and surrounding NC lung
tissue at least 2 cm away from the tumor were biochemically quenched
by flash-freezing in liquid N2 (36, 38). The margins of the tumor were
initially assessed by the surgeon by visual inspection. Parallel tissue
samples were sent to on-site pathologists for confirmation of the diagnosis and the cancer-free margins. The remaining specimen was preserved in buffered formalin for detailed pathological examination.
Sample preparation. The frozen tissue samples were pulverized
to a particle size of less than 10 μm in liquid N2 using a Spex freezer
mill (Spex). Polar and nonpolar metabolites were extracted from the
ground tissue, which also yielded insoluble protein residues (21, 42).
The protein residues were extracted by homogenization in 2% SDS,
62.5 mM Tris, and 1 mM DTT buffer for protein determination using
the Pierce BCA method (Thermo Fisher Scientific).
Electrophoresis, Western blotting, immunohistochemistry, cell proliferation, and colony-formation assays. Detailed protocols are described
in the Supplemental Methods.
shRNA knockdown of PC in lung cancer cells. NSCLC cells lines
and HEK 293T cells obtained from ATCC were grown in DMEM
media containing 0.45% glucose and 4 mM glutamine at 37°C, 95%
relative humidity, and 5% CO2. HEK 293T cells were transfected
with pCMV and pMD2.G vectors carrying viral packaging (gag, pol,
rev) and envelope (VSV-G) genes, along with a plasmid containing shRNA against PC (shPC54 or shPC55), shEV, or shScr (Mission
shRNA; Sigma-Aldrich). The anti-PC sequences used were: shPC54:
CCGGGCCCAGTTTATGGTGCAGAATCTCGAGATTCTGCACCATAAACTGGGCTTTTTG; shPC55: CCGGGCCAAGGAGAACAACGTAGATCTCGAGATCTACGTTGTTCTCCTTGGCTTTTTG.
After 48 hours, medium from the transfected cells was collected,
filtered, supplemented with 16 μg/ml polybrene, and added to
NSCLC cell lines in an equal volume of DMEM media. Fresh media
were added to the 293T cells, and after 24 hours, transduction of
the NSCLC cells was repeated. The resulting NSCLC cells bearing
the plasmid with the puromycin resistance gene were selected using
1 μg/ml puromycin.
Tracer studies in cell cultures. Cells transduced with shEV, shScr,
shPC54, or shPC55 were incubated in DMEM in the presence of 10
mM 13C6-glucose or 2 mM 13C5,15N2-glutamine for 24 hours, quenched
in cold acetonitrile, and extracted in acetonitrile/water/chloroform
(v/v 2:1.5:1), as described previously (10).
Tracer studies in mouse xenografts of PC-knockdown cells. To assess
tumor growth of PC-knockdown A549 cells, 6-week-old female NOD/
SCID gamma (NSG) mice (n = 6 mice/group) (The Jackson Laboratory)
were injected s.c. with 8 × 106 cells containing either shEV or shPC55
mixed with Matrigel (BD Biosciences). The tumor diameters were
determined 3 times per week by caliper. Tumor sizes were calculated
as πab/4, where a and b are the lengths of the maximum and minimum
dimensions. After 36 days, the mice were injected via the tail vein with
10

100 μl 1.075 M [U-13C]-glucose 3 times at 15-minute intervals. Blood
samples were taken intraorbitally immediately after the first injection
and at sacrifice 60 minutes later. The tumors were immediately excised
and weighed prior to flash-freezing in liquid N2. Metabolites were
extracted as described above (43).
Tracer studies in ex vivo tissue slices. These experiments were performed on fresh slices of paired tumor and nontumorous lung tissues
resected from individual patients (26). Upon lung resection, thin
slices (0.5–1 mm thick) of tissue were excised using a Weck microtome in the operating room. These slices were immediately placed
in T-flasks containing DMEM with the appropriate tracer (either
10 mM [U-13C]-glucose or 2 mM [U-13C,15N]-glutamine), and then
transferred to a CO2 incubator set at 37°C and 5% CO2. The flasks
were continuously rocked for 24 hours for aeration and to maintain
constant nutrient supplies at the tissue surface, while avoiding local
buildup of waste products such as acids. The slices were then washed
in cold PBS, frozen in liquid N2, pulverized as described above,
and extracted for polar and nonpolar metabolites and proteins as
described above for cell cultures.
SIRM analysis. Polar metabolite fractions from cells, patient tissues,
and mouse tumors were analyzed by GC-MS, NMR, and FT-ICR-MS
as previously described (10, 42). Nonpolar fractions were analyzed
for lipids by FT-ICR-MS as previously described (10, 28). 13C fractional enrichments were calculated for metabolite isotopomers
(13C at different atomic positions) and isotopologs (different numbers of 13C atoms) as the level of a given isotopomer or isotopolog
divided by the summed level of all isotopomers or isotopologs. The
absolute levels of labeled metabolites were obtained by normalizing
the moles of metabolites to the extractable protein content.
Statistics. Statistical analyses were conducted using SPSS 19.0
(IBM- Somers) and Kaleidagraph (Synergy Software). Differences
between patient cohorts were assessed using the paired Wilcoxon
test, the 2-tailed Student t test on the logarithms of the values
(i.e., for fractional differences), and by examining the distribution
terms of the mean, median, and modal values. The expression ratios
(CA/NC) for PC or GLS were highly non-normally distributed, and
the mean, median, and modal values were calculated accordingly. The
modal values were estimated from the maximum in the frequencyversus-ratio histograms and were thus slightly affected by the bin size.
Mouse tumor sizes were tested using an unpaired Welch’s version of the t test (44). First, the significance was evaluated at each
time point after injection. Second, all growth curves were fitted
to different models, including exponential, power, and quadratic
growth, and best-fit parameters with the associated standard deviations were subjected to Welch’s t test. The simplest form that gave
good fitting statistics was a simple quadratic equation: size = a + bt2.
In this form, a is the initial tumor size at t = 0, and b is the specific
growth rate. Third, the tumor weights at necropsy were compared
as 2 groups. The significance of differences between shEV and shPC
groups in terms of proliferation and metabolites was determined
using Welch’s t test. In all analyses, a P value of less than 0.05 was
considered significant.
Study approval. This study was approved by the IRB of the University of Louisville. Written informed consent was obtained from all
subjects prior to inclusion in this study. The murine tumor protocol was
performed in compliance with all relevant laws and institutional guidelines and was approved by the IACUC of the University of Louisville.
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